Neplodnost - problém přelomu tisíciletí: Literatura

09.02.2010 19:06

 Přehled literatury

   1. Gould D., C., Petty R. and Jacobs H.S: Education and Debate: The male menopause-does it exists? Brit. Med. J. 320: 858,2000. 
   2. Diczfalusy E.: An Aging humankind: is our future behind us? Aging Male 1:8, 1998. 
   3. Kaufman J.M.: Hypotalamic-pituitary-gonadal function in aging men. Aging Male 2:157, 1999. 
   4. United Nations Department for Economical and Social Information and Policy Analysis. Population Division. World population prospects: The 1994 Revision. United nations, New York, Doc. 145, 1995. 
   5. United Nations Secretariat, Department of Economic and Social Affairs, Populations Division. The 1998 Revision. ESA/P/WP.150. New York: United Nations, 1998. 
   6. Diclafuzy E.: Voyage into our common future: from futurophobia to futuriphilia. Aging Male 3:37,2000. 
   7. World Health Organization. Epidemiology and Prevention of Cardiovascular Disease in Elderly People. WHO Technical reports, Geneva. WHO, 1995. 
   8. Ferriní R.L. and Barrett-Connor E.: Sex hormones and age: a cross-sectional study of testosterone and estradiol and their bioavailable fractions in community-dwelling men. Am. J. Epidemiol. 147:750, 1998. 
   9. Cheon J., Sung B.M., Kim J. J., Yoon D. and Koh S.K.: Osteroporosis in patients receiving total androgen blockade therapy for prostate cancer. J. Urol. 159 (Abst. 1291):336, 1998. 
   10. Bernhard P.H. and Niewochner C.: Effects of early hormonal therapy on bone in asymptomatic men with prostate cancer. J. Urol. 159 (Abst. 1298):338, 1998. 
   11. Liebenluft E., Schmidt P.J., Turner E.H., Danaceu M.A., Ashman S.B., Wehr TA. and Rubinow D.R: Effects of luprolide-induced hypogonadism and testosterone replacement on sleep, melatonín and prolactin secretion in men. J. Clin. Endocrinol. Metab. 82:3202, 1997. 
   12. Oslcece J.: Melatonin and the aging male. Aging Male, 1 (Suppl. 1):9, 1999. 
   13. Veldhuis J.D.: Male hypothalamic-pituitary-gonadal axis. In: Infertility in the Male, 3rd edition. Edited by LA Lipshultz and SS Howards. St.Louis: Mosby-Year Book, 1997, pp. 23-58. 
   14. Santen R.J., Bardin C.W.: Episodic luteinizing hormone secretion in man: Pulse analysis, clinical interpretation, physiologic mechanism. J. Clin. Invest 1973,52:2617. 
   15. McLure R.D.: Endocrine investigation and therapy. Urol. Clin. North. Am. 14(3):471-488, 1987.  
   16. Bagatell C.J., Bremner W.J.: Drug therapy: Androgens in Men - Uses and Abuses (review article). N. Engl. Med. 334(11):707-714, 1996. 
   17. Baulieu KE.: Dehydroepiandrosterone (DHEA): A fountain of youth? J. Clin. Endocrinol. Metab 81(9):3147, 1996. 
   18. Vermeulen A.: Dehydroepiandrosterone sulfate and aging. Ann. NY Acad. Sci. 774:121, 1995. 
   19. Legrain S., Massien Ac., Lahlou N. et al: DHEA replacement administration: pharmacokinetic and pharmacodynamic studies in healthy elderly subjects. J. Endocrinol. Metab. 85:30208,2000. 
   20. De Boer H., Block G.J., Van der Veen E.A.: Clinical aspects of growth hormone deficiency in adults. Endocrinology Rev. 16:63, 1995. 
   21. Veldhuis J.D.: Elements in the pathophysiology od disemined growth hormone (GH) secretion in aging humans. Endocrine 7:41, 1997. 
   22. Kleinberg D.L, Melmed S.: The adult GH deficiency syndrome: signs, symptoms and diagnosis. The Endocrinologist. 8:8(S), 1998. 
   23. Holmes S.J., Economou G., Whitehouse R.W., Adams J.E. and Shalet S.M.: Reduced bone mineral density in patients with adult onset growth hormone deficiency. J. Clili. Endocrinol. Metab. 78:669, 1994. 
   24. Block D.J., de Boer H., Gooren L.J.G. and Van der Veen E.A.: Growth hormone substitution in adult growth-hormone deficient men arguments androgen effect on the skin. Clin. Endocrinol. 47:29, 1997. 
   25. Baum H.R, Biller B.M.K, Finkelstein J.S., Cannistraro K.R, Oppenheim D.S., Schonfeld D.A., Michel T.H., Wittink H. and Klibanski A.: Effects of physiologie growth hormone therapy on bone density and body composition in patients with adult -onset growth hormone deficiency. A randomized placebo controled trial. Ann. Int. Med. 125:883, 1996. 
   26. Lesee G.P., Frase W.D., Farqhuarson R, Hipkin L. and Vora J.I.: Gonadal status is an important determinant of bone density in acromegaly. Clin. Endocrinol. 48:59, 1998. 
   27. Hintz R, Attie .KM., Baptista J. and Roche A.: N. Engl. J. Med. 340:502, 1999. 
   28. Sonata W.E., Lynch C.D., Coney P.T. and Hutches P.M.: Decreases in cerebral microvasculature with age associated with decline in growth hormone and insulin-like growth factor-I. Endocrinology 138:3515, 1997. 
   29. Baum H.B.A., Katznelso L, Sherman J.C., Biller B.M.K, Hayden D.L, Sehonfeld D.A., Cannistraro KE. and Klibanski A.: Effects of psychological growth hormone (GH) therapy in cognition and quality of life in patients with adult -onset GH deficiency. J. Clin. Endocrinol. Metab. 83:3184, 1998. 
   30. Kleinberg D.L, Melamed S.: The adult growth hormone deficiency syndrome: signs, symptoms and diagnosis. The Endocrinologist. 8:8s-14s, 1998. 
   31. Rosenfalck A.M., Maghsoudi S., Fisker S. et al.: The effect of 30 month replacement therapy with recombinant human GH on insulin and e-peptide kinetics and body composition in GH-deficient adults. J. Clin. Endocrinol. Metab. 85:4173,2000. 
   32. Fernholm R., Bramnert M. Hagg E.: Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease. J. Clili. Endocrinol. Metab. 85:4104,2000. 
   33. Janssen Y.H.J., Doorbos J., Roelfsma F.: Changes in muscle volume, strength, and
 bioenegetics during recombinat GH therapy in adults with GH deficiency. J. Clin. EndocrinoL Metab. 84:279,2000. 
   34. Dall R., Lonbogardi S., Ehrnborg C. et al.: The effect of 4 week supraphysiological GH administration on the insulin-like growth factor axis in women and men. J. Clin. Endocrinol. Metab. 85:4193,2000. 
   35. Harman S.M., Metter E.J., Blackman M., R. et al.: Serum levels of IGF-l, IGF-2, IGF-binding protein-3 and prostate specific antigen as predictors of clinical prostate cancer. J. Clin. Endocrin. Metab. 85:4258, 2000. 
   36. Van Cauter E., Leproult R. and Plat L.: Age-related changes in slow wave and REM sleep and relationship with GH and cortisollevels in healthy men. JAMA 284:861, 2000. 
   37. Liu R.Y., Zhou J.N., Heerikhuize van J., Hofman M.A. and Swaab D.F.: Decreased melatonin levels in post-mortem cerebro-spinal fluid in relation to ageing, Alzheimer's disease and apoliprotein E 4/4 genotype. J. Clin. Endocrin. Metab. 84:323, 1999. 
   38. Dittgen M. and Hoffmann H.: New dosage form for pulsatile delivery of melatonin: development and testing in animal and human subjects. Aging Male 1:141, 1998. 
   39. Sewerynek E., Melchirri D., Reiter R.J., Ortiz G.G. and Lewinski A.: Lipopolysacharide induced hepatotoxicity is inhibited by the antioxidant melatonin. Eur. J. PharmacoL 293:327, 1995. 
   40. Maestroni G.J.M.: The immunoneuroendocrine role of melatonin. J. PineaL Res. 14:1, 1993 
   41. 0lcese J.: Melatonin and the aging male. Aging male 1 (Suppl.1):9, 1998. 
   42. 0lcese J.: Cellular and molecular mechanism mediating melatonin action. Aging Male 1:113,1998. 
   43. Liu R., Zhou J., Heerikhuise J. et al: Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging. Alzheimer's disease and apolipoprotein E-4/4 genotype. J. Clin. Endocrin. Metab. 84:323, 2000. 
   44. Blackman M.R.: Age-related alterations in sleep quality and neuroendocrine function. JAMA 284:879, 2000. 
   45. Bray G.A. and York D.A.: Leptin and clinical medicine: a new piece in the puzzle of obesity. J. Clin. Endocrin. Metab. 82:2771, 1997. 
   46. Luukkaa V., Personen D., Huhtaniemi I., Lehtonen A., Tilvis R, Tuomilehto J., Kouli M. and Huupponen R.: Inverse correlation between serum testosterone and leptin in men. J. Clin. Endocrin. Metab. 83:3243, 1998. 
   47. Behere H.M., Simoni M. and Nieschlag E.: Strong association between leptin and testosterone. Clin. Endocrin. 47:237, 1997 
   48. Marin P.: Effects of androgens in men with the metabolic syndrome. Aging Male 1:129, 1998. 
   49. Gooren L.J.G.: The age-related decline of androgen levels in men: clinically significant? Br. J. UroL 78:763, 1996. 
   50. Burris A.S., Banks S.M., Carter C.S., Davidson T.M. and Sheris R.J.: A long term prospective study of the physiological and behavioral effects of hormone replacement in untreated hypogonadal men. J. Androl 13:297, 1992. 
   51. Alexander G.M., Swerdloff R.S., Wang C., Davidson T., McDonald V., Steiner B. and Hines M.: Androgen behavior correlations in hypogonadal and eugonadal men: Cognitive abilities. Hormones and Behavior 33:85, 1998. 
   52. Urban R.J., Bodenburg Y.H., Gilkinson C., Fowworth J., Coggan A.R, and Wolfe R.R: Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am. J. PhysioL 269:820, 1995. 
   53. Tenover J.S.: Androgen administration to aging men. EndocrinoL Metab. Clin. N.A. 23:877, 1994. 
   54. Hibberts N.A., Howell A.E. and Randall V.A.: Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than these from non-balding scalp. J. Endocrinol.156:59, 1998.
   55. Abu E.O., Horner A., Krusec V., Triffitt J.T. and Compston J.E.: The localization of androgen receptors in human bone. J. Clin. Endocrinol. Metab. 82:3493, 1997. 
   56. Vermeulen A. and Kaufman J.M.: Aging of the hypothalamo-pituitary-testicular axis in men. Hormone Res. 43:25, 1995. 
   57. Plymate S.R, Tenover J.S. and Bremmer W.J.: Circadian variation in testosterone, sex hormone binding globulin and calculated non-sex hormone binding globulin bound testosterone in healthy young men and elderly men. J. Androl. 10:366, 1989. 
   58. Nieschlag E., Lemmers U. and Freischman C.W.: Reproductive function on fathers and grandfathers. J. Clin. Endocrinol. Metab. 55:676, 1982. 
   59. Nickel J.C., Fradet Y. and Boake R, Pommerville P., Perrault J.P., Afridi S. and Elhilali M.: Placebo therapy in benign prostatic hyperplasia. J. Urol. 157:330 (Abstract 1289), 1997. 
   60. Vaughn E.D. and Cox D.S.: Chronic administration of dehydroepiandrosterone (DHEA) does not increase serum testosterone or prostatic specific antigen (PSA) in normal men. J. Urol. 159 (Abst. 280):27, 1998. 
   61. Majewska M.D.: Neuronal activities of DHEAS. Ann. N.Y. Acad. Sci. 74:111,1996. 
   62. Mellon S.H.: Neurosteroids: biochemistry, modes of action and clinical relevance. J. Clin. Endocrinol. Metab. 78: 1003, 1994. 
   63. Christianssen K.H.: Behavioral correlates of and dehydroepiandrosterone sulfate. Aging male 1:103, 1998. 
   64. Weksler M.E.: Hormone replacement for men - not enough evidence to recommend routine treatment with dehydroepiandrosterone. Br. Med. J. 312:859, 1996. 
   65. Herbert J.: The age of dehydroepiandrosterone. Lancet 345: 1193, 1995.

66. Morales A.J., Nolan J.J. and Nelson J.C.: Effects of replacement dose of dehydroepiandrosterone in men and women of advacing age. Clin. Endocrinol. Metab. 78:1360, 1994. 
   67. Kropman R.F., Verdijk R.M., Lyklama A.A.B., Nijeholt A. and Roelfsma E: Routine endocrine screening in impotence: Significance and cost-effectiveness. Int. J. Impotence Res. 3:87, 1991. 
   68. Vermeulen A.: Routine endocrine screening in impotence: significance and cost effectiveness. Editorial. Int. J. Impotence Res. 3:85, 1991. 
   69. Buvat J. and Lemaire A.: Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J. Urol. 158: 1764, 1997. 
   70. Morales A., Johnston B., Heaton J.W.P. and Lundie M.: Testosterone supplementation in hypogonadal impotence: assessment of biochemical measurements and therapeutic outcomes. J. Urol. 157:849, 1997. 
   71. Vermeulen A., Verdonck L., Kaufman J.M.: A clinical evaluation of simple methods for the estimation of the testosterone in serum. 1. Clin. Endocrinol. Metab. 84:3666, 1999. 
   72. Finkelstein J.S., Kilbanski A., Neer R.M., Doppelt S.H., Rosenthal D.I., Segre G.Y. and Crowley W.E: Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J. Clin. Endocrinol. Metab. 69:776, 1989. 
   73. Morales A., Johnston B., Heaton J.W.P. and Clark A.: Oral androgens in the treatment of hypogonadal impotent men. J. Urol. 152:1115, 1994. 
   74. Bagatell C.J., Bremmer W.J.: Drug therapy: androgens in men - uses and abuses. Eng. J. Med. 334:707, 1996. 
   75. Bagatell C.J., Bremmer W.J.: Androgen and testosterone effect on plasma lipids. Prog. Cardiovasc. Dis. 38:255, 1995. 
   76. Gooren L.J.G.: A ten year safety study of the oral androgen testosterone undecanoate. Androl. 15:212, 1994. 
   77. Sokol R.Z., Palacios A. and Campfield L.A.: Comparison of the kinetics of injectable
 testosterone in eugonadal and hypogonadal men. Fertil. Steril. 37, 1982. 
   78. Bhasin S.: Androgen treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 74: 1221, 1992. 
   79. Nankin H.R: Hormone kinetics after intramuscular testosterone cypionate. Fertil. Steril. 47: 1004, 1967. 
   80. Bhasin S. and Bremmer W.J.: Emerging issues in androgen replacement therapy. J. Clin. Endocrin. Metab. 82:3, 1997. 
   81. Tan K.C., Shiu S.W., Pang R.W., Kung A.W.: Effects of testosterone replacement on HDL subfractions and apolipoprotein A/I containing lipoproteins. Clin. Endocrinol. 48:187, 1998. 
   82. Ulrich D.H.: Effects of androgens on hemostasis Maturitas 24:147, 1996. 
   83. Jockenhovel F., Vogel E., Reinhardt W., Reinwein D.: The effects of various modes of androgen substitution therapy on erythropoiesis. Eur. J. Med. Res. 2:293, 1997. 
   84. Bradin S.W., Swerdloff R.S., Santen R.J.: Androgens: risks and benefits. J. Clin. Endocrinol. Metab. 73:4, 1991. 
   85. Svetek D.A., Canby E.D., Thompson LM., Sabenegh E.S.: The effects of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction. J. Urol. 158:1775, 1997. 
   86. Ozata M., Bulur M., Beyhan A. et al.: Effects of gonadotropin and testosterone treatments on prostate volume serum prostate specific androgen levels in male hypogonadism. Endocrine J. 44:419, 1997. 
   87. Douglas T.H., Connelly R.R, McLeod D.G. et al.: The effect of exogenous testosterone replacement on prostate specific androgen and prostate specific membrane androgen levels in hypogonadal men. J. Surg. Oncol. 59:246, 1995. 
   88. McClellan K.J., Goa K.L: Transdermal testosterone. Drugs. 55:253, 1998 
   89. Winters S.J., Atkinson L.: Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that aging enhances testosterone negative feedback. Clin. Endocrinol. 47: 317, 1997. 
   90. Arver S., Meike A.W., Dobs A.S., Mazer N.A.: Permeation enhanced testosterone transdermal systems in the treatment of male hypogonadism: long term effects. J. Endocrinol. 148:254, 1996. 
   91. Cunningham G.R, Cordero E., Thomby J.: Testosterone replacement with transdermal therapeutical systems: physiologic serum testosterone and elevated dihydrotestosterone levels. JAMA 261:2525, 1989. 
   92. Findlay J.C., Place V., Synder P.J.: Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J. Clin. Endocrinol. Metab. 68:369, 1989. 
   93. Meikle A.W., Arver S., Dobs A.S. et al.: Effects of a permeation enhanced transtestosterone transdermal system on prostate parameters in previously treated or untreated hypogonadal male. Br. J. urol. (Abst. 157):38, 1996. 
   94. Findlay J.C., Place V., Snyder P.J.J.: Treatment of primary hypogonadism in men by the transdermal administration of testosterone. J. Clin. Endocrinol. Metab. 68:369, 1989. 
   95. Jordan W.P., Atkinson L.E.: Comparison of the skin irritation potential of two testosterone transdermal systems: an investigational system and a marketed product. Clin. Therapeutics 20:80, 1998. 
   96. Jordan W.P.: Allergy and topical irritation associated with transdermal testosterone administration: a comparison of scrotal and non-scrotal transdermal systems. 
   97. Wang C., Berman N., Longstrenth J.A. et al.: Pharmacokinetic of transdermal T gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85:964,2000. 
   98. Wang C., Swerdloff R.S., Iranmanesh A. et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 85:2389,2000.
   99. Comhaire E.: Personal communication. December, 2000. 
   100. Handelsman D.J., MacKey M.A., Howe C. et al.: An Analysis of Testosterone Implants for Androgen Replacement Therapy. Clin. Endocrinol. 47:311, 1997. 
   101. Bhasin S., Swerdloff R.S. and Steiner R: A biodegradable testosterone 10-11 weeks in hypogonadal men. J. Clin. Endocrinol. Metab. 74:75, 1992. 
   102. Van Eckardstein A. and Nieschlag E.: Pharmacology, pharmacokinetics and effect/side effects of different androgen preparations. Aging Male 1:28, 1998. 
   103. Willson J.D.: Androgen abuse by athletes. Endocrin. Rev. 9:181, 1988. 
   104. Buckley W.D., Yesalis C.E., Friedl K.E. et al.: Estimated prelevance of anabolic steroid use among high school seniors. 
   105. Elashof J.D., Jacknow A.D., Shain S.G. et all: Effect of androgenic anabolic steroids on muscular strength. Ann Int. Med. 115:387, 1991. 
   106. American College of Sport Medicine position stand on the use of anabolic steroids in sports. Med. Sci. Sports Exerc. 19:534, 1987. 
   107. Bagatell C. and Bremner W.J.: Androgens in men: uses and abuses. N. Engl. J. Med. 334:707, 1996. 
   108. Stanley H.L., Schmidt R.P., Poses R.M. et al.: Does hypogonadism contribute to the occurrence of minimal trauma hip facture in elderly men? J. Amer. Geriatr. Soc. 39:766, .1991. 
   109. Tenover J.S.: Effect of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75: 1092, 1992. 
   110. Katznelson L., Finkelstein J.S., Schoenfeld D.A., Rosenthal D.I. et al.: Increased bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. 81:4358, 1996. 
   111. Snyder P.J., Peachey H., Hanoush P. et al.: Effect of testosterone on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab. 84:1966, 1999. 
   112. Reid I.R, Wattie D.J., Evans M.C. et al.: Testosterone therapy in glucocorticoid treated men. Arch. Int. Med. 156:1173, 1996. 
   113. Sili R., Morley J.E., Kaiser E.E. et al.: Testosterone replacement in older hypogonadal men: a 12 month randomized, controlled trial. J. Clin. Endocrinol. Metab. 82:1661, 1997. 
   114. Snyder P.J., Peachey H., Hannoush P. et al.: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab. 84:2547, 1999. 
   115. Morley J .E., Pery H.M., Kaiser EE. et al.: Effects of testosterone replacement therapy in old hypogonadal men. J. Am. Geriatr. Soc. 41:149, 1993. 
   116. Urban RJ., Bodenburg Y.H., Gilkinson C. et al.: testosterone administration in elderly men increases skeletal muscle strength and protein synthesis. Am. J. Physiol. 269:E820, 1995. 
   117. Clague J.E., Wu F.C.W., Horan M.A.: Difficulties I measuring the effect of testosterone replacement therapy on muscle function in older men. Int. J. Androl. 22:261, 1999. 
   118. Hajjar R.R, Kaiser F.E., Morley J.E.: Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82:3793, 1997. 
   119. Crook D.: Androgen therapy in the aging male: assesing the effect on heart disease. Aging Male 2:151, 1999. 
   120. Sanbloom R.E., Matsumoto A.M., Schoene R.R. et al.: Obstructive sleep apnea induced by testosterone administration. N. Engl. J. Med. 308:508, 1983. 
   121. Santamaria J.D., Prior J.C., Fleetham J.A.: Reversible reproductive dysfunction in men with obstructive sleep apnea. Clin. Endourol (Oxf) 28:461, 1988. 
   122. Svetec D.A., Canby E.D., Thompson D.M. et al.: The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunctions.J. Urol. 158: 1775, 1997. 
   123. Douglas T.H., Connelly R.R., McLeon D.G. et al.: Effects of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men. J. Surg. Oncol. 59:246, 1995. 
   124. Zqliczynski S., Ossowski M., Slowinska-Srzednicka J. et al.: Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121:35, 1996. 
   125. Bhere H.M., Kleish S., Leifke E., Link T.M. and Nieschlag E.: Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82:2386, 1997. 
   126. Morales A., Bain J., Ruijs A., Chapdelaine A. and Tremblay R.R.: Clinical practice quidelines for screening and monitoring male patients receiving testosterone supplementation therapy. Int. J. Impotence Res. 8:95, 1996. 
   127. Tremblay R.R. and Morales A.: Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1:213, 1998.